CellaVision appoints new CFO

CellaVision announced today that Magnus Blixt has been appointed Chief Financial Officer (CFO), effective May 2, 2013.

Magnus Blixt will take overall responsibility for the Group's Finance and Administration function and will be part of the management team. Magnus Blixt holds an MBA, and has extensive experience in running small and medium sized companies focusing business performance and process improvements. He most recently held the position as Business Demand Manager at SKF AB. Previous experience includes a position as CFO at SKF Polyseal Inc. in the U.S., Operations Manager and Business Controller at SKF Sealing Solutions ESP and a number of economic and finance positions, including Rotaform AB.

Magnus Blixt succeeds Sven-Åke Henningsson, Member of the Board, who has been Acting CFO since September 2012.

For further information please contact:
Yvonne Mårtensson, CEO, CellaVision AB
Tel: +46 708 33 77 82 | Epost: yvonne.martensson@cellavision.com

About CellaVision
CellaVision is an innovative, global medical technology company that develops and sells its own leading systems for routine analysis of blood and other body fluids in health care services. The analyses often constitute important reference data for fast and correct diagnosis of illnesses, for example of infections and serious cancers. CellaVision's products rationalize manual laboratory work, and secure and support effective workflows and skills development within and between hospitals. The company has leading-edge expertise in image analysis, artificial intelligence and automated microscopy. In 2012 sales were SEK 170 million and sales continue to increase, with a growth target of at least 15 % per year over an economic cycle. CellaVision's registered office is in Lund and the company has subsidiaries in the USA, Canada and Japan. The share is listed on the Nasdaq OMX Stockholm, Small Cap list. Read more at www.cellavision.com.

This information was released for public disclosure on April 19, 2013 at 8.25 am CET.